WuXi AppTec taps Altasciences to support IND platform

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/MangoStar_Studio)
(Image: Getty/MangoStar_Studio)

Related tags: Investigational new drug, Wuxi apptec, Clinical research, CRO, IND applications, Altasciences

Altasciences will work with WuXi AppTec to support its investigational new drug platform designed to manage and accelerate IND applications.

The contract research organization (CRO), Altasciences, will provide its clinical pharmacology, first-in-human and proof-of-concept trials, program management and other full-service solutions to support early phase clinical services for WIND, WuXi AppTec’s investigational new drug (IND) platform.

The platform combines CRO services with program management and regulatory support for IND applications.

Per the agreement, Altasciences will provide full-service early phase clinical solutions to the partnership to support the addition of the IND platform. Altasciences has agreed to provide clinical pharmacology, first-in-human and proof-of-concept trials, program management, and data management, among other services to streamline early phase clinical processes for WuXi’s IND programs.

A spokesperson for WuXi Apptec told us, “The objective of WIND is to support the full scope of drug development programs, from IND-enabling studies to document preparation and submission. By partnering with Altasciences, WuXi can be more flexible with scheduling multiple components of the drug development process from lead candidate selection through to proof of concept, therefore, accelerating the IND process.”

WuXi Clinical, the clinical CRO arm of WuXi AppTec will manage the partnership between the two companies. The WuXi AppTec spokesperson told us the clinical arm had been looking to partner in North America in an aim to complement its current Phase I offering and support the IND platform.

Additionally, a number of senior executives at Altasciences have previously worked at WuXi, which the company believes will build a true collaboration, according to the WuXi spokesperson.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us


View more